vs
Side-by-side financial comparison of Ametek (AME) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
Ametek is the larger business by last-quarter revenue ($2.0B vs $1.5B, roughly 1.3× BeOne Medicines Ltd.). Ametek runs the higher net margin — 19.9% vs 4.4%, a 15.5% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 13.4%). Ametek produced more free cash flow last quarter ($527.3M vs $379.8M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 7.3%).
AMETEK, Inc. is an American multinational conglomerate and global designer and manufacturer of electronic instruments and electromechanical devices with headquarters in the United States and over 150 sites worldwide.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
AME vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.0B | $1.5B |
| Net Profit | $398.6M | $66.5M |
| Gross Margin | 36.0% | 90.5% |
| Operating Margin | 25.3% | 12.4% |
| Net Margin | 19.9% | 4.4% |
| Revenue YoY | 13.4% | 32.8% |
| Net Profit YoY | 2.9% | 143.8% |
| EPS (diluted) | $1.73 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $1.9B | $1.4B | ||
| Q2 25 | $1.8B | $1.3B | ||
| Q1 25 | $1.7B | $1.1B | ||
| Q4 24 | $1.8B | $1.1B | ||
| Q3 24 | $1.7B | $1.0B | ||
| Q2 24 | $1.7B | $929.2M | ||
| Q1 24 | $1.7B | $751.7M |
| Q4 25 | $398.6M | $66.5M | ||
| Q3 25 | $371.4M | $124.8M | ||
| Q2 25 | $358.4M | $94.3M | ||
| Q1 25 | $351.8M | $1.3M | ||
| Q4 24 | $387.3M | $-151.9M | ||
| Q3 24 | $340.2M | $-121.3M | ||
| Q2 24 | $337.7M | $-120.4M | ||
| Q1 24 | $310.9M | $-251.2M |
| Q4 25 | 36.0% | 90.5% | ||
| Q3 25 | 36.3% | 86.1% | ||
| Q2 25 | 35.8% | 87.5% | ||
| Q1 25 | 36.1% | 85.2% | ||
| Q4 24 | 36.6% | 85.8% | ||
| Q3 24 | 36.0% | 83.0% | ||
| Q2 24 | 36.0% | 85.1% | ||
| Q1 24 | 34.1% | 83.4% |
| Q4 25 | 25.3% | 12.4% | ||
| Q3 25 | 25.8% | 11.5% | ||
| Q2 25 | 26.0% | 6.7% | ||
| Q1 25 | 26.3% | 1.0% | ||
| Q4 24 | 26.6% | -7.0% | ||
| Q3 24 | 26.1% | -12.0% | ||
| Q2 24 | 25.8% | -11.5% | ||
| Q1 24 | 24.0% | -34.8% |
| Q4 25 | 19.9% | 4.4% | ||
| Q3 25 | 19.6% | 8.8% | ||
| Q2 25 | 20.2% | 7.2% | ||
| Q1 25 | 20.3% | 0.1% | ||
| Q4 24 | 22.0% | -13.5% | ||
| Q3 24 | 19.9% | -12.1% | ||
| Q2 24 | 19.5% | -13.0% | ||
| Q1 24 | 17.9% | -33.4% |
| Q4 25 | $1.73 | $0.05 | ||
| Q3 25 | $1.60 | $0.08 | ||
| Q2 25 | $1.55 | $0.06 | ||
| Q1 25 | $1.52 | $0.00 | ||
| Q4 24 | $1.67 | $-0.10 | ||
| Q3 24 | $1.47 | $-0.09 | ||
| Q2 24 | $1.45 | $-0.09 | ||
| Q1 24 | $1.34 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $458.0M | $4.5B |
| Total DebtLower is stronger | $2.3B | $836.4M |
| Stockholders' EquityBook value | $10.6B | $4.4B |
| Total Assets | $16.1B | $8.2B |
| Debt / EquityLower = less leverage | 0.21× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $458.0M | $4.5B | ||
| Q3 25 | $439.2M | $4.0B | ||
| Q2 25 | $619.7M | $2.8B | ||
| Q1 25 | $399.0M | $2.5B | ||
| Q4 24 | $374.0M | $2.6B | ||
| Q3 24 | $396.3M | $2.7B | ||
| Q2 24 | $396.6M | $2.6B | ||
| Q1 24 | $373.8M | $2.8B |
| Q4 25 | $2.3B | $836.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $10.6B | $4.4B | ||
| Q3 25 | $10.5B | $4.1B | ||
| Q2 25 | $10.4B | $3.8B | ||
| Q1 25 | $10.0B | $3.5B | ||
| Q4 24 | $9.7B | $3.3B | ||
| Q3 24 | $9.6B | $3.4B | ||
| Q2 24 | $9.3B | $3.4B | ||
| Q1 24 | $9.0B | $3.4B |
| Q4 25 | $16.1B | $8.2B | ||
| Q3 25 | $16.2B | $7.6B | ||
| Q2 25 | $15.3B | $6.3B | ||
| Q1 25 | $14.9B | $5.8B | ||
| Q4 24 | $14.6B | $5.9B | ||
| Q3 24 | $14.8B | $5.8B | ||
| Q2 24 | $14.8B | $5.7B | ||
| Q1 24 | $14.9B | $5.7B |
| Q4 25 | 0.21× | 0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.3M | $417.3M |
| Free Cash FlowOCF − Capex | $527.3M | $379.8M |
| FCF MarginFCF / Revenue | 26.4% | 25.4% |
| Capex IntensityCapex / Revenue | 2.9% | 2.5% |
| Cash ConversionOCF / Net Profit | 1.47× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $1.7B | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.3M | $417.3M | ||
| Q3 25 | $440.9M | $402.6M | ||
| Q2 25 | $359.1M | $263.6M | ||
| Q1 25 | $417.5M | $44.1M | ||
| Q4 24 | $550.0M | $75.2M | ||
| Q3 24 | $487.2M | $188.4M | ||
| Q2 24 | $381.4M | $-95.6M | ||
| Q1 24 | $410.2M | $-308.6M |
| Q4 25 | $527.3M | $379.8M | ||
| Q3 25 | $420.0M | $354.5M | ||
| Q2 25 | $329.8M | $219.8M | ||
| Q1 25 | $394.5M | $-12.3M | ||
| Q4 24 | $498.3M | $-17.3M | ||
| Q3 24 | $460.9M | $54.7M | ||
| Q2 24 | $360.0M | $-205.5M | ||
| Q1 24 | $382.6M | $-465.1M |
| Q4 25 | 26.4% | 25.4% | ||
| Q3 25 | 22.2% | 25.1% | ||
| Q2 25 | 18.5% | 16.7% | ||
| Q1 25 | 22.8% | -1.1% | ||
| Q4 24 | 28.3% | -1.5% | ||
| Q3 24 | 27.0% | 5.5% | ||
| Q2 24 | 20.8% | -22.1% | ||
| Q1 24 | 22.0% | -61.9% |
| Q4 25 | 2.9% | 2.5% | ||
| Q3 25 | 1.1% | 3.4% | ||
| Q2 25 | 1.6% | 3.3% | ||
| Q1 25 | 1.3% | 5.0% | ||
| Q4 24 | 2.9% | 8.2% | ||
| Q3 24 | 1.5% | 13.3% | ||
| Q2 24 | 1.2% | 11.8% | ||
| Q1 24 | 1.6% | 20.8% |
| Q4 25 | 1.47× | 6.28× | ||
| Q3 25 | 1.19× | 3.22× | ||
| Q2 25 | 1.00× | 2.79× | ||
| Q1 25 | 1.19× | 34.71× | ||
| Q4 24 | 1.42× | — | ||
| Q3 24 | 1.43× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 1.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AME
| Transferred At Point In Time | $1.1B | 54% |
| Electronic Instruments Group | $620.1M | 31% |
| Transferred Over Time | $294.6M | 15% |
ONC
Segment breakdown not available.
